Skip to content
Companies

Terremoto Biosciences

Selective AKT1 inhibitors for breast cancer and solid tumors

Raised to date

$40.7M

of $108.6M offered across 1 Form D filing

Still open
$67.9M
Investors
14
Last filed
Apr 22, 2026

About

Terremoto Biosciences is a clinical-stage biotechnology company in South San Francisco developing small-molecule medicines built on novel covalent chemistry. Its work centers on AKT1-selective inhibitors intended to engage the target inside tumor cells while sparing other AKT isoforms. The lead program, TER-2013, is in a Phase 1 trial in breast cancer and other solid tumors with PI3K/AKT/PTEN pathway alterations, and a second molecule, TER-4480, is in IND-enabling studies for hereditary hemorrhagic telangiectasia. The company closed a $108 million Series C in April 2026 to fund clinical development of both programs.

Covalency technologies that make previously undruggable sites addressable, yielding isoform-selective AKT1 inhibitors that avoid the hyperglycemia and rash toxicities that limited earlier pan-AKT drugs and their narrow therapeutic windows.

Funding

  • EquityFiled Apr 22, 2026Form D
    $40.7M/ $108.6M

Product

TER-2013

Clinical-stage oncology therapeutic

An orally available, AKT1-selective small-molecule inhibitor in a Phase 1 clinical trial (NCT-07109726) for breast cancer and other solid tumors carrying PI3K/AKT/PTEN pathway alterations.

  • Orally available small molecule
  • AKT1 isoform selectivity built on covalent chemistry
  • Targets tumors with PI3K/AKT/PTEN pathway alterations

Built for

Patients with PI3K/AKT/PTEN-altered solid tumors and patients with hereditary hemorrhagic telangiectasia, reached through oncologists and specialist centers; longer term, pharmaceutical partners and payers.

People on file